

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# 东曜药业

## TOT BIOPHARM International Company Limited

### 東曜藥業股份有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1875)**

## RE-DESIGNATION OF EXECUTIVE DIRECTOR TO NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”, its members individually or collectively, “**Director(s)**”) of TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, due to adjustments to the Group’s business strategies and her personal career arrangements, Ms. Yeh-Huang, Chun-Ying (黃純瑩女士) (“**Ms. Yeh-Huang**”) will be re-designated from an executive Director to a non-executive Director of the Company with effect from 1 January 2023 (the “**Re-designation**”) and will be responsible for the oversight of strategy formulation and development and public relations of the Group. Ms. Yeh-Huang will also resign from her position as a senior manager of TOT BIOPHARM Co., Ltd. (東曜藥業有限公司) (“**TOT Suzhou**”), a wholly-owned subsidiary of the Company, and her position as the general manager of TOT BIOPHARM Company Limited (東源國際醫藥股份有限公司) (“**TOT Taipei**”), a wholly-owned subsidiary of the Company, on 1 January 2023 (“**Other Position Changes**”). Following the Re-designation and Other Position Changes, Ms. Yeh-Huang will remain as the Vice Chairperson of the Board, a member of the Strategy and ESG Committee of the Board and a director of TOT Suzhou.

Ms. Yeh-Huang will enter into a new letter of appointment with the Company in relation to her Re-designation as a non-executive Director for the previously agreed three-year fixed term ending on 11 March 2025. Her directorship will be subject to retirement by rotation and re-election pursuant to the articles of association of the Company. Ms. Yeh-Huang is entitled to an annual director’s fee of USD80,000 as a non-executive Director. The remuneration of Ms. Yeh-Huang is determined by the Board with reference to her contributions, experience and relevant duties and responsibilities within the Company.

Ms. Yeh-Huang confirmed that she has no disagreement with the Board and there is no matter relating to the Re-designation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. The Board would like to take this opportunity to express its sincere gratitude to Ms. Yeh-Huang for her valuable contribution to the Company during her tenure of office as an executive Director.

## **Biographical details of Ms. Yeh-Huang**

Ms. Yeh-Huang, aged 63, joined the Group on 5 July 2010 and was appointed as an executive Director and the Vice Chairperson of the Board on 19 January 2016 and 15 October 2020, respectively. Following the Re-designation and Other Position Changes, she will be a non-executive Director and will remain as the Vice Chairperson of the Board, a member of the Strategy and ESG Committee of the Board and a director of TOT Suzhou. For Ms. Yeh-Huang's work experience prior to joining the Group, please refer to page 25 of the 2021 Annual Report published by the Company on 28 April 2022.

Ms. Yeh-Huang obtained a bachelor's degree in pharmacy from Taipei Medical College (now known as Taipei Medical University) in Taiwan in June 1982 and obtained her Taiwan license of pharmacist in June 1983.

As at the date of this announcement, Ms. Yeh-Huang is the beneficial owner of 7,115,700 ordinary shares of the Company ("**Shares**"). Within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), she is also interested in (i) 1,162,500 Shares as the holder of outstanding share options granted under the pre-IPO share option scheme of the Company (adopted on 20 February 2013 and subsequently amended from time to time); and (ii) 2,897,383 Shares as a beneficiary of a trust, which represent her interests in the Shares granted under the restricted share award scheme of the Company (adopted on 29 May 2020 and subsequently amended from time to time) and held by Teeroy Limited on trust for her.

Save as disclosed above, as at the date of this announcement, Ms. Yeh-Huang confirms that (i) she did not hold any directorship in other listed public companies in Hong Kong or elsewhere in the past three years; (ii) she does not hold any other positions with the Company and/or its subsidiaries; (iii) she does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (iv) there is no other information that should be disclosed pursuant to the requirements under Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 30 December 2022

*As at the date of this announcement, the executive Directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive Directors of the Company are Mr. Fu, Shan and Mr. Qiu, Yu Min; and the independent non-executive Directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.*